List gastrointestinal complications.
Meconium ileus: failure to pass the first stool in neonates (meconium usually passes within the first 24–48 hours after birth)
Etiology: Cystic fibrosis is the cause in > 90% of cases.
Clinical findings: signs of a distal small bowel obstruction (thick meconium plugs the distal ileum)
Bilious vomiting
Abdominal distention
No passing of meconium or stool
Diagnostics
X-ray abdomen (with contrast agent)
Dilated small bowel loops
Microcolon: narrow caliber of the colon, as it is still unused (meconium has not been passed through yet)
Neuhauser sign (soap bubble appearance): a mottled or bubble-like appearance in the distal ileum and/or cecum as a result of meconium mixing with swallowed air [39]
Air-fluid levels are uncommon because of the viscous consistency of meconium.
Treatment
Enema with a contrast agent
Surgery is required in complicated cases (e.g., intestinal perforation, volvulus)
Small bowel obstruction: can also occur in older children and adults
Distal intestinal obstruction syndrome (DIOS) : blockage of the small intestines by thickened stool in the distal ileum and right colon
Highest prevalence in the second and third decades of life
Tends to occur in individuals with pancreatic insufficiency
Clinical manifestations include abdominal pain and distention, a palpable cecal mass, and flatulence.
Describe respiratory complications.
Allergic bronchopulmonary aspergillosis (ABPA): ∼ 10% of individuals with CF develop this condition. [41][42]
Pulmonary emphysema
Pneumothorax
Cor pulmonale
Describe the prognosis.
Median life expectancy: 39 years
Individuals with CF who have pancreatic sufficiency tend to present with mainly pulmonary symptoms in late childhood/early adulthood and generally have a milder course of disease
The main determinant of life expectancy is the severity of pulmonary disease: chronic respiratory infections and mucus plugging → bronchiectasis (irreversible) → progressive respiratory failure → death
Describe the prevention.
Annual influenza vaccine for all affected individuals > 6 months with inactivated influenza vaccine
Pneumococcal vaccine (see ”Immunization schedule”)
Palivizumab: antibody against respiratory syncytial virus (RSV) for infants < 24 months
Long-term treatment with azithromycin may be used to prevent recurrent pulmonary infections.
Zuletzt geändertvor 2 Jahren